Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Robust Pipeline Aims to Address Unmet Needs 5
2.2 High level of Innovation in the Sepsis and Tuberculosis Pipelines. 5
2.3 Opportunities to obtain innovative first-in-class products remain. 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.2 Symptoms 10
4.2.1 Pneumonia 10
4.2.2 MRSA 11
4.2.3 Sepsis 11
4.2.4 Tuberculosis 11
4.3 Diagnosis 11
4.4 Pathophysiology 15
4.5 Prognosis 17
4.5.1 Tuberculosis 17
4.5.2 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 17
4.5.3 Pneumonia 17
4.5.4 Sepsis 17
4.6 Treatment Options 18
4.6.1 Cell-Wall Synthesis Inhibitors 18
4.7 Overview of Marketed Products within Antibacterial Therapies 20
5 Assessment of Pipeline Product Innovation 21
5.1 Overview 21
5.2 Antibacterial Pipeline by Phase, Molecule Type and Molecular Target 21
5.2.1 Antibacterial Pipeline Overall 21
5.2.2 Key Antibacterial Indications 22
5.3 Pipeline by Molecular Target 24
5.3.1 Antibacterial Disease Overall 24
5.3.2 Key Antibacterial Indications 25
5.4 Comparative Distribution of Programs between the Antibacterial Therapeutics Market and Pipeline by Therapeutic Target Family 27
6 Signaling Pathways, and First-in-Class Molecular Target Integration. 36
6.1 The Complexity of Signaling Networks in Antibacterial therapies 36
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 36
6.3 First-in-Class Target Matrix Assessment 36
6.3.1 Sepsis 37
6.3.2 MRSA 38
6.3.3 Pneumonia 38
6.3.4 Tuberculosis 39
7 First-in-Class Target and Pipeline Program Evaluation 40
7.1 Pipeline Programs that Target XXX 40
7.2 Pipeline Programs that Target XXX 41
7.3 Pipeline Programs that Target XXX 42
7.4 Pipeline Programs that Target XXX 44
7.5 Pipeline Programs that Target XXX 45
7.6 Pipeline Programs that Target XXX 46
7.7 Pipeline Programs that Target XXX 48
7.8 Pipeline Programs that Target XXX 2 49
8 Deals and Strategic Consolidations 51
8.1 Industry-Wide First-in-Class Deals 51
8.2 Licensing Deals 52
8.2.1 Deals by Region, Value and Year 52
8.2.2 Deals by Stage of Development and Value 54
8.2.3 Deals by Molecule Type, Molecular Target and Value 54
8.2.4 Table for Licensing Deals with a Disclosed Value 55
8.3 Co-development Deals 57
8.4 List of First-in-Class Pipeline Products with and without Prior Deal Involvement 62
9 Appendix 67
9.1 Pipeline 67
9.2 References 96
9.3 Abbreviations 99
9.4 Disease List 100
9.4.1 Tuberculosis: 100
9.4.2 Pneumonia 100
9.4.3 MRSA 100
9.4.4 Sepsis: 100
9.5 Research Methodology 100
9.5.1 Data integrity 101
9.5.2 Innovative and meaningful analytical techniques and frameworks: 101
9.5.3 Evidence based analysis and insight: 101
9.6 Secondary Research 101
9.6.1 Market Analysis 101
9.6.2 Pipeline Analysis 101
9.6.3 First-in-Class Matrix Assessment 101
9.6.4 First-in-Class Target Profiles 102
9.6.5 Licensing and Co-Development Deals 102
9.7 Contact Us 102
9.8 Disclaimer 102